SCD highlights at ASH 2023: disease pathogenesis, ongoing clinical trials & novel gene therapies
149 بار بازدید -
7 ماه پیش
-
In this discussion, Rabi Hanna,
In this discussion, Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, and Josu de la Fuente, PhD, FRCP, FRCPI, FRCPCH, FRCPath, Imperial College London, London, UK, share key highlights in sickle cell disease (SCD) presented at ASH 2023. Dr Hanna and Dr de la Fuente first discuss updates in the pathogenesis of SCD, highlighting the role of ineffective erythropoiesis. Following this, the experts summarize data emerging from the RISE UP trial (NCT05031780), which is exploring the safety and efficacy of mitapivat in patients with SCD. Dr Hanna and Dr de la Fuente then go on to discuss the excitement surrounding novel gene therapies, highlighting two agents: exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel), and conclude by commenting on other gene-editing approaches being explored in the field. This discussion took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
7 ماه پیش
در تاریخ 1402/10/19 منتشر شده
است.
149
بـار بازدید شده